Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
limosilactobacillus fermentum WIS32
- Development stage
- Preclinical
- Lead developer
- CAS Weizhi
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Limosilactobacillus fermentum WIS32 is an investigational live biotherapeutic product, which is a specific strain of the probiotic bacterium *Limosilactobacillus fermentum*. [9] It is being studied as an adjunctive treatment for major depressive disorder (MDD). [2] The proposed mechanism of action involves modulation of the microbiota-gut-brain axis. [2] Preclinical research suggests that `L. fermentum WIS32` can improve depressive-like behaviors by altering the gut microbiota, which in turn increases the levels of serotonin (5-HT) and brain-derived neurotrophic factor (BDNF) in the hippocampus, while also inhibiting the expression of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6. [2] The probiotic is being provided for clinical trials by CAS Weizhi (Beijing) BioTech Co., Ltd.
Beyond the preview
Go deeper on limosilactobacillus fermentum WIS32.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on limosilactobacillus fermentum WIS32.